Study protocol for a randomised trial evaluating the non-inferiority of stepped palliative care versus early integrated palliative care for patients with advanced lung cancer

Kathryn E Post, Lauren B Heuer, Arif H Kamal, Pallavi Kumar, Madeleine Elyze, Sarah Griffith, Jacqueline Han, Fred Friedman, Ashley Jackson, Chardria Trotter, Rachel Plotke, Charu Vyas, Vicki Jackson, Dustin J Rabideau, Joseph A Greer, Jennifer S Temel, Kathryn E Post, Lauren B Heuer, Arif H Kamal, Pallavi Kumar, Madeleine Elyze, Sarah Griffith, Jacqueline Han, Fred Friedman, Ashley Jackson, Chardria Trotter, Rachel Plotke, Charu Vyas, Vicki Jackson, Dustin J Rabideau, Joseph A Greer, Jennifer S Temel

Abstract

Introduction: Integrating palliative care (PC) early in the illness course for patients with serious cancers improves their outcomes and is recommended by national organisations such as the American Society of Clinical Oncology. However, monthly visits with PC clinicians from the time of diagnosis can be challenging to implement due to the lack of specialty-trained PC clinicians and resources. Therefore, we developed a stepped care model to triage PC service based on patients' needs.

Methods and analysis: We are conducting a non-blinded, randomised trial to evaluate the non-inferiority of a stepped PC model compared with an early integrated PC model for improving patients' quality of life (QOL) at 24 weeks (primary outcome). Patients assigned to early integrated PC meet with PC every 4 weeks throughout their illness. Patients assigned to stepped PC have PC visits only at clinically significant points in their illness (eg, cancer progression) unless their QOL decreases, at which time they are 'stepped up' and meet with PC every 4 weeks throughout the remainder of their illness. Secondary aims include assessing whether stepped PC is non-inferior to early integrated PC regarding patient-clinician communication about end of life care and length of stay on hospice as well as comparing resource utilisation. Patients are recruited from the Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Duke Cancer Center, Durham, North Carolina and University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania. The target sample size is 510 patients.

Ethics and dissemination: The study is funded by the National Cancer Institute, approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board and will be reported in accordance with the Consolidated Standards of Reporting Trials statement. We will disseminate results through professional society meetings, peer-reviewed publications and presentations to patient organisations.

Trial registration number: NCT03337399.

Keywords: adult oncology; adult palliative care; protocols & guidelines; respiratory tract tumours.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials; QOL, quality of life.
Figure 2
Figure 2
Eligibility criteria. NSCLC, non-small cell lung cancer; PC, palliative care.

References

    1. Rabow MW, Dibble SL, Pantilat SZ, et al. . The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med 2004;164:83–91. 10.1001/archinte.164.1.83
    1. Bakitas MA, Tosteson TD, Li Z, et al. . Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the enable III randomized controlled trial. J Clin Oncol 2015;33:1438–45. 10.1200/JCO.2014.58.6362
    1. Bakitas M, Lyons KD, Hegel MT, et al. . Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project enable II randomized controlled trial. JAMA 2009;302:741–9. 10.1001/jama.2009.1198
    1. Dionne-Odom JN, Azuero A, Lyons KD, et al. . Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes from the enable III randomized controlled trial. J Clin Oncol 2015;33:1446–52. 10.1200/JCO.2014.58.7824
    1. Zimmermann C, Swami N, Krzyzanowska M, et al. . Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014;383:1721–30. 10.1016/S0140-6736(13)62416-2
    1. Temel JS, Greer JA, Muzikansky A, et al. . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–42. 10.1056/NEJMoa1000678
    1. Ferrell B, Sun V, Hurria A, et al. . Interdisciplinary palliative care for patients with lung cancer. J Pain Symptom Manage 2015;50:758–67. 10.1016/j.jpainsymman.2015.07.005
    1. Greer JA, Jackson VA, Meier DE, et al. . Early integration of palliative care services with standard oncology care for patients with advanced cancer. CA Cancer J Clin 2013;63:349–63. 10.3322/caac.21192
    1. Ferrell BR, Temel JS, Temin S, et al. . Integration of palliative care into standard oncology care: American Society of clinical oncology clinical practice guideline update. J Clin Oncol 2017;35:96–112. 10.1200/JCO.2016.70.1474
    1. Dans M, Kutner JS, Agarwal R. NCCN clinical practice guidelines in oncology, palliative care (version 2.2021). National comprehensive cancer network. Available: [Accessed 5 Apr 2021].
    1. Hui D, Elsayem A, De la Cruz M, et al. . Availability and integration of palliative care at US cancer centers. JAMA 2010;303:1054–61. 10.1001/jama.2010.258
    1. Lupu D, American Academy of Hospice and Palliative Medicine Workforce Task Force . Estimate of current hospice and palliative medicine physician workforce shortage. J Pain Symptom Manage 2010;40:899–911. 10.1016/j.jpainsymman.2010.07.004
    1. van Straten A, Hill J, Richards DA, et al. . Stepped care treatment delivery for depression: a systematic review and meta-analysis. Psychol Med 2015;45:231–46. 10.1017/S0033291714000701
    1. Breslin FC, Sobell MB, Sobell LC, et al. . Toward a stepped care approach to treating problem drinkers: the predictive utility of within-treatment variables and therapist prognostic ratings. Addiction 1997;92:1479–89. 10.1111/j.1360-0443.1997.tb02869.x
    1. Jakicic JM, Tate DF, Lang W, et al. . Effect of a stepped-care intervention approach on weight loss in adults: a randomized clinical trial. JAMA 2012;307:2617–26. 10.1001/jama.2012.6866
    1. Azizi M, Sapoval M, Gosse P, et al. . Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015;385:1957–65. 10.1016/S0140-6736(14)61942-5
    1. Kroenke K, Krebs EE, Wu J, et al. . Telecare collaborative management of chronic pain in primary care: a randomized clinical trial. JAMA 2014;312:240–8. 10.1001/jama.2014.7689
    1. Krebber AMH, Jansen F, Witte BI, et al. . Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trial. Ann Oncol 2016;27:1754–60. 10.1093/annonc/mdw230
    1. Jansen F, Krebber AMH, Coupé VMH, et al. . Cost-Utility of stepped care targeting psychological distress in patients with head and neck or lung cancer. J Clin Oncol 2017;35:314–24. 10.1200/JCO.2016.68.8739
    1. Singer S, Danker H, Briest S, et al. . Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (stepped care): study protocol for a cluster randomized controlled trial. Trials 2014;15:482. 10.1186/1745-6215-15-482
    1. Salloum A, Wang W, Robst J, et al. . Stepped care versus standard trauma-focused cognitive behavioral therapy for young children. J Child Psychol Psychiatry 2016;57:614–22. 10.1111/jcpp.12471
    1. Fokkenrood HJP, Scheltinga MRM, Koelemay MJW, et al. . Significant savings with a stepped care model for treatment of patients with intermittent claudication. Eur J Vasc Endovasc Surg 2014;48:423–9. 10.1016/j.ejvs.2014.04.020
    1. Cella D. The functional assessment of cancer Therapy-Lung and lung cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Semin Oncol 2004;31:11–15. 10.1053/j.seminoncol.2004.04.008
    1. Sangha O, Stucki G, Liang MH, et al. . The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156–63. 10.1002/art.10993
    1. El-Jawahri A, Traeger L, Park ER, et al. . Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer. Cancer 2014;120:278–85. 10.1002/cncr.28369
    1. Carver CS. You want to measure coping but your protocol's too long: consider the brief cope. Int J Behav Med 1997;4:92–100. 10.1207/s15327558ijbm0401_6
    1. Hagan TL, Fishbein JN, Nipp RD, et al. . Coping in patients with incurable lung and gastrointestinal cancers: a validation study of the brief cope. J Pain Symptom Manage 2017;53:131–8. 10.1016/j.jpainsymman.2016.06.005
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13. 10.1046/j.1525-1497.2001.016009606.x
    1. Chouaid C, Agulnik J, Goker E, et al. . Health-Related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol 2013;8:997–1003. 10.1097/JTO.0b013e318299243b
    1. EuroQol Group . EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. 10.1016/0168-8510(90)90421-9
    1. O'Brien MER, Ciuleanu T-E, Tsekov H, et al. . Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441–7. 10.1200/JCO.2006.06.5821
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. Greer JA, Tramontano AC, McMahon PM, et al. . Cost analysis of a randomized trial of early palliative care in patients with metastatic nonsmall-cell lung cancer. J Palliat Med 2016;19:842–8. 10.1089/jpm.2015.0476
    1. Hay JW, Smeeding J, Carroll NV, et al. . Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health 2010;13:3–7. 10.1111/j.1524-4733.2009.00663.x
    1. Pronovost P, Angus DC. Cost reduction and quality improvement: it takes two to tango. Crit Care Med 2000;28:581–3. 10.1097/00003246-200002000-00055
    1. Drummond MF, Sculpher MJ, Claxton K. Methods for economic evaluation of health care programmes. 4th ed. New York, NY: Oxford University Press, 2015.
    1. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796–7. 10.1056/NEJMp1405158
    1. Temel JS, Greer JA, El-Jawahri A, et al. . Effects of early integrated palliative care in patients with lung and Gi cancer: a randomized clinical trial. J Clin Oncol 2017;35:834–41. 10.1200/JCO.2016.70.5046
    1. Hirsch FR, Suda K, Wiens J, et al. . New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016;388:1012–24. 10.1016/S0140-6736(16)31473-8
    1. Howlader N, Forjaz G, Mooradian MJ, et al. . The effect of advances in lung-cancer treatment on population mortality. N Engl J Med 2020;383:640–9. 10.1056/NEJMoa1916623

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe